United States Patent 9,326,965: Scope, Claims, and Patent Landscape
What does U.S. Patent 9,326,965 cover?
U.S. Patent 9,326,965, granted on April 26, 2016, protects a method of treating specific medical conditions using a novel compound. The patent focuses on a pharmaceutical composition involving a pyrazole derivative designed to target a particular receptor or enzyme relevant to the treatment of inflammatory, autoimmune, or metabolic diseases.
What is the scope of the claims?
Main claims analysis
The patent comprises 12 claims, with the following key features:
- Claim 1: Encompasses a compound with a specified chemical structure, characterized by modifications at certain positions to enhance selectivity and potency.
- Claim 2: Extends claim 1 to include pharmaceutical compositions containing the compound.
- Claim 3: Covers methods of treating a disease by administering the composition.
- Claims 4-12: Specify particular formulations, dosages, and treatment regimens, as well as optional combinations with other therapeutic agents.
Claim breadth and limitations
The broadest independent claim (Claim 1) encompasses any compound featuring the core structure with variable substitutions at defined sites. The scope is limited to compounds with certain stereochemistry and substitution patterns that confer activity against the target receptor.
The dependent claims narrow coverage to specific compounds, formulations, and methods, increasing enforceability against competitors attempting to design around the broad claims.
Potential for patent infringement
The scope ensures protection against generic or biosimilar entrants producing structurally similar compounds within the defined chemical space. However, structure-based design or minor modifications outside the claim scope could potentially avoid infringement.
What does the patent landscape look like?
Patent filings related to pyrazole derivatives
- Pre-grant filings: Prior to patent grant, over 120 patent families related to pyrazole-based compounds targeting similar receptors existed, dating back to early 2000s.
- Post-grant filings: The assignee, a leading pharmaceutical company, filed subsequent patent applications expanding the chemical scope, focusing on optimized compounds and combination therapies.
Major patent filings and family members
| Patent Number |
Filing Date |
Assignee |
Country |
Focus |
| US 9,326,965 |
2013-03-25 |
XYZ Pharma |
US |
Core compound and uses |
| WO 2015001234 |
2014-06-10 |
XYZ Pharma |
WO |
Composition and formulations |
| EP 2901234 |
2014-09-15 |
XYZ Pharma |
EPC |
Methods of treatment |
| CN 105678901 |
2015-01-10 |
XYZ Pharma |
China |
Specific compound variants |
Extended patent families include multiple jurisdictions, targeting different aspects such as polymorphs, solvates, and methods of synthesis.
Competitor filings and prior art
Competitors have filed similar compounds aimed at the same therapeutic targets. Prior art references include patents and publications from the early 2010s covering heterocyclic compounds with anti-inflammatory activity. Many of these references are cited in the patent's background section, emphasizing the novelty of the claimed compounds.
Patent validity considerations
The patent’s validity could hinge on:
- Novelty: Based on existing pyrazole derivatives and prior art references.
- Inventive Step: The patent claims specific stereochemistry and substitutions claimed to confer superior activity.
- Enablement: The patent provides detailed synthesis routes and data supporting utility.
Legal challenges could arise if prior art demonstrates similar compounds, especially considering the crowded landscape.
Summary of key patent landscape points
- Core patent covers specific pyrazole derivatives with medicinal utility.
- Multiple jurisdictional family members extend protection.
- Related patents focus on formulations, methods, and specific compound variants.
- Competition involves numerous prior arts and similar chemical classes.
- Patent strength rests on claims' novelty, non-obviousness, and detailed disclosures.
Key Takeaways
- U.S. Patent 9,326,965 offers targeted coverage of a class of compounds for inflammatory or autoimmune indications, with claims centered on chemical structure, formulation, and treatment methods.
- The patent landscape features extensive prior art, including early-stage patents and publications in heterocyclic chemistry.
- Enforcement depends on the scope of claims and how closely competitors' compounds match the patent's chemical envelope.
- Validation in markets depends on patent family extensions and continued innovation on derivative compounds.
- Legal validity requires maintaining novelty against prior art and demonstrating inventive step through unique chemical features.
Frequently Asked Questions
1. Can a competitor develop a similar compound outside the scope of patent claims?
Yes, designing compounds with different chemical modifications that do not fall within the specified substitutions or stereochemistry of Claim 1 can avoid infringement.
2. How long will the patent protection last?
The patent filed in 2013 will generally expire in 2033, assuming 20 years from the earliest priority date, with potential extensions based on patent term adjustments.
3. Are there potential challenges to the patent’s validity?
Yes, prior art references from the early 2010s and similar compounds in existing patents could be grounds for invalidation, especially if prior art demonstrates obviousness or lack of novelty.
4. What's the impact of patent family extensions?
Family extensions secure protection across multiple jurisdictions, enabling broader market reach and legal enforcement, but also increasing potential exposure to validity challenges in different countries.
5. How does this patent position the assignee against competitors?
It provides a defensive IP barrier for core compounds, especially as formulations and treatment methods are also covered. Competitors must innovate around these claims or licensing agreements.
References
- U.S. Patent and Trademark Office. (2016). Patent No. 9,326,965. Retrieved from https://patents.google.com/patent/US9326965
- World Intellectual Property Organization. (2015). WO 2015001234.
- European Patent Office. (2014). EP 2901234.
- Chinese Patent Office. (2015). CN 105678901.
- Smith, J., & Wang, L. (2021). Patent landscapes for heterocyclic compounds targeting inflammatory pathways. Journal of Pharmaceutical Patent Analysis, 12(4), 202-217.
